

# Effect of Calcium Dobesilate (CaD) on Diabetic Macular Edema Treated by Intravitreal Ranibizumab

**Dongxuan Wang**

Changyi People's Hospital

**Hui Wang**

Changyi People's Hospital

**Shuang Wu** (✉ [cymyyyk1234@126.com](mailto:cymyyyk1234@126.com))

Changyi People's Hospital

**Xueqiu Yang**

Changyi People's Hospital

**Jiansen Xu**

Changyi People's Hospital

---

## Research Article

**Keywords:** Calcium dobesilate, Ranibizumab, Diabetic macular edema, Best corrected visual acuity, Central macular thickness

**Posted Date:** August 31st, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-830956/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Calcium dobesilate (CaD) had been used in the treatment of diabetic retinopathy (DR) due to its potential in protecting against retinal vascular damage. However, it did not reduce the risk of development of diabetic macular edema (DME). The aim of this study was to investigate the effect of CaD plus intravitreal ranibizumab in the treatment of DME.

**Methods:** This retrospective, observational, consecutive case control study enrolled patients newly diagnosed with DME who received intravitreal ranibizumab (IVR) administration with 3-monthly loading dose injection followed by pro re nata (3+PRN) regimen with or without CaD orally daily for at least 12-month follow-up. Medical records and optical coherence tomography (OCT) results were reviewed and compared at baseline and at 3, 6, and 12 months after injection.

**Results:** A total of 102 eyes from 102 patients were enrolled in this study. Fifty-four patients received IVR combined with CaD orally (IVR+CaD group), while forty-eight patients received IVR solely (IVR group). No statistically significant differences were found in the general condition of patients between the two groups at baseline ( $P > 0.05$ ). At every follow-up, 3, 6 and 12 months after injection, the best corrected visual acuity (BCVA) improved and the central macular thickness (CMT) decreased in both groups when compared with those at baseline ( $P < 0.05$ ), while there were no significant differences in BCVA improvement and CMT reduction between the two groups ( $P > 0.05$ ). The mean number of ranibizumab injections in R+C group was significantly lower than that in R group ( $5.4 \pm 1.1$  injections versus  $6.7 \pm 1.6$  injections,  $P < 0.05$ ) within 1-year treatment. No adverse events were found in neither groups.

**Conclusions:** Adding oral CaD to intravitreal ranibizumab was demonstrated to have similar effectiveness and safety for improving visual function and restoring the anatomy of the retina in macular with fewer injections in DME patients.

## Background

Diabetic macular edema (DME), characterised by exudative fluid accumulation in the macula, is the leading cause of visual impairment in patients with diabetes mellitus (DM)[1, 2]. The blood retinal barrier (BRB) is vital for maintaining the normal structure and function of the retina, and DME is caused by its failure[3]. The disruption of BRB is associated with an increase in the level of vascular endothelial growth factor (VEGF), intercellular adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and other inflammatory factors[3]. Therefore, anti-VEGF[4, 5] and other anti-inflammatory agents[6] become the main treatment way to deal with DME after laser photocoagulation. Although intravitreal aflibercept, bevacizumab, or ranibizumab had been proved to improve vision function in eyes with center-involved DME in a comparative effectiveness randomized clinical trial conducted by Diabetic Retinopathy Clinical Research Network [7], there were still a significant number of patients with poor response to anti-VEGF treatment or without sustained improvement in visual acuity. Although VEGF inhibitor therapy had been shown to be a cost-effective treatment for DME that had

reduced the incidence of vision loss and could reduce the associated economic and social cost[8], continuous intravitreal injection treatment also brings a high economic burden to patients, especially in developing countries. Therefore, intravitreal anti-VEGF agents in combined with other therapy, such as intravitreal triamcinolone acetonide[9], or Rho-kinase inhibitor[10], or methotrexate[11], subthreshold micropulse laser[12, 13], macular grid laser photocoagulation[14], sub-tenon steroid injection[15], or switching anti-VEGF treatment to intravitreal dexamethasone implant[6, 16–18], was investigated in DME patients.

Calcium dobesilate (CaD) is a vascular protective drug that has been used in DR treatment in past decades[19–21] by its effect in preventing the oxidative stress and inflammation[22]. It can protect blood vessels and improve circulation by lowering blood viscosity, inhibiting platelet activity and reducing capillary permeability[23, 24]. Nonetheless, the potential beneficial effects of CaD on DME patients when combined with intravitreal anti-VEGF agents was still not clear. Therefore, in this study, we investigated the effectiveness and safety of combined therapy of CaD with anti-VEGF agents in patients with DME. The primary outcome of this study was BCVA and CMT change after the treatment and the second outcome was the number of ranibizumab injections administered during the follow-up period.

## Methods

### Patient selection

A retrospective, observational, case control study was conducted on patients with treatment-naïve center-involved DME (CIDME), who received intravitreal ranibizumab treatment in the department of ophthalmology, Changyi People's Hospital with one-year follow-up period. Patients with type 2 diabetes mellitus and clinically significant DME, according to the criteria developed by ETDRS[25] were included in the study, and the flowchart (Fig. 1) indicated the protocol to select the patients.

This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Changyi People's Hospital. Informed consent was obtained from all of the patients or their guardians before initiation of intravitreal pharmacotherapy. The medical records were retrospectively reviewed after approval was received from the Institutional Review Board, Changyi People's Hospital.

### Data collection

The clinical data retrieved from medical records included demographic information, general medical history, history of any previous ocular conditions, previous treatments for DME. All participants underwent a detailed ophthalmologic examination, including best corrected visual acuity (BCVA), slit-lamp biomicroscopy, intraocular pressure measurement, fundus examination under pupil dilation, and macular scan by SD-OCT (Cirrus HD-OCT with software version 6.0; Carl Zeiss Meditec, Dublin, CA, USA), before the treatment and at each follow-up. The central macular thickness (CMT) was defined as the retinal thickness of the central 1.0 mm at OCT B-scan.

In addition, the occurrence of any complications during the perioperative period and postoperative follow-up were also analyzed for safety evaluation.

## Treatment protocol

A 3 + PRN regimen was used in this study. After 3-monthly loading dose injection of intravitreal ranibizumab (IVR), patients received re-injection if needed. The criteria for re-injection was similar as described previously[26]. At each visit, patients underwent visual acuity assessment and OCT scan for macular thickness assessment. If BCVA and OCT were stable for 2 consecutive visits, reinjection was suspended, while if worsening of BCVA (> 5 letter loss) or OCT (increase > 10%) was noticed at follow-up, reinjection was given.

In IVR group, patients received IVR injection only as mentioned above, while in IVR + CaD group, patients received capsules of CaD (1500 mg per day in three divided doses of 500 mg) besides IVR injection.

## Statistical analysis

All data were analyzed using the SPSS (version 11.5, SPSS Inc., Chicago, IL, USA). BCVA measurements were converted to logMAR equivalents for statistical analysis. Pearson chi-square test was used for comparative analyses of categorical variables. The independent sample t-test and paired t-test were employed to analyze changes in BCVA and CFT. For all statistical tests,  $p < 0.05$  was considered significant.

## Results

Between January 2017 and March 2020, 102 patients (mean age of  $57.72 \pm 9.91$ , range of 42-69 years) were enrolled in the present study, which 63 patients (61.76%) were male and 39 patients (38.24%) were female. Fifty-four patients, who received IVR combined with CaD orally, were referred as IVR+CaD group, while forty-eight patients, who received IVR solely, were referred as IVR group.

Table 1 shows the baseline characteristics for the study population. There was no significant difference between the two groups in terms of gender, age, history of smoking and drinking, other comorbidities except diabetes, the course of diabetes and HbA1c.

As shown by table 2, after IVR administration with 3-monthly loading dose injection, the BCVA (logMAR) significantly increased from  $0.35 \pm 0.12$  to  $0.24 \pm 0.09$  ( $p \leq 0.05$ ) in IVR group and increased from  $0.32 \pm 0.15$  to  $0.23 \pm 0.10$  ( $p \leq 0.05$ ) in IVR+CaD group, and the BCVA maintained satisfactory during the treatment until the end of the follow-up in both groups. Meantime, the CMT significantly decreased from  $427 \pm 172 \mu\text{m}$  to  $286 \pm 69 \mu\text{m}$  ( $p \leq 0.05$ ) in IVR group and decreased from  $412 \pm 185 \mu\text{m}$  to  $277 \pm 92 \mu\text{m}$  ( $p \leq 0.05$ ) in IVR+CaD group, and the CMT also maintained during the treatment until the end of the follow-up in both groups. No significant difference was found in BCVA and CMT between two groups at baseline and every follow-up period.

Within one year of IVR treatment by 3+PRN regimen, the mean injection number in IVR group was  $6.7 \pm 1.6$ , which was significantly more than that in IVR+CaD group ( $5.4 \pm 1.1$ ,  $p=0.05$ ).

As for complications during the treatment, there were no ocular complications, such as endophthalmitis, vitreous hemorrhage, and retinal detachment, and no serious systemic adverse events such as cerebral infarction or myocardial infarction in neither groups.

## Discussion

DME, also considered as diabetic maculopathy, is one of the most important causes of vision loss among people with diabetes around the world[2]. Although the advent of anti-VEGF agents has greatly improved the treatment effect of DME patients, and intravitreal injection of anti-VEGF agents has become the first line therapy for DME, there are still some patients who response poorly to the treatment.

CaD (calcium 2,5-dihydroxybenzenesulfonate) is a vascular protective drug which has been proved to have beneficial effects in vascular diseases such as chronic venous insufficiency and haemorrhoids[27] and is extensively used to treat diabetic retinopathy[28–30], choronic venous insufficiency[31] and multiple microangiopathic diseases[32]. In previous studies, the potential mechanisms of CaD improving microcirculation and reducing micro-vascular injury had been investigated as follows[21]: (1) reducing platelet aggregation caused by thrombin or collagen[33]; (2) significantly protecting peritoneal vascular from reactive oxygen species (ROS) effects of penetration[34]; (3) inhibiting capillary permeability[35]; (4) alleviating the chronic inflammatory state and improving endothelial cell function[36, 37]; (5) reducing endothelial shedding by the synthesis and release of nitric oxide (NO)[38]; (6) reducing platelet aggregation by inhibiting prostaglandin and reduce erythrocyte aggregation and viscosity of suspension[24]; (7) down-regulating the expression of VEGF and fibroblast growth factor (FGF) to inhibit vascular endothelial cell proliferation[39]; (8) restoring autophagy by inhibiting the VEGF/PI3K/AKT/mTOR signaling pathway[40]. Therefore, based on these mechanisms mentioned above, CaD should be effective in the treatment of macular edema. However, in previous studies on the treatment of DME, CaD was found to show neither effect on reducing the risk of development of DME[27], nor statistically significant difference when compared with placebo in respect to combining with laser photocoagulation on the macular thickness in DME patients[41]. These results made it controversial for the role of CaD in the treatment of macular edema. When we reviewed the literatures about the treatment of CaD for DME, we found that both the two studies were published relatively early, which were earlier than the wide application of anti-VEGF agents in clinic, and no studies had explored the effectiveness and safety of oral CaD combined with anti-VEGF treatment. Therefore, our findings, for the first time, showed that compared with anti-VEGF monotherapy, CaD combined with anti-VEGF agents had the similar effect in improving visual function and reducing the CMT in DME patients, and it could reduce the number of intravitreal injection and decrease the economic burden during the 1-year follow-up period.

So far, although the exact mechanism of DME is still unclear, abnormally increased levels of VEGF and inflammatory mediators, and subsequently the breakdown of BRB was considered to play vital role in the

formation of macular edema in diabetes[2]. Accordingly, with the emergence of anti-VEGF and anti-inflammatory agents, they gradually became the first-line treatment[42, 43] or treatment with good prospects[44, 45]. The effect of CaD on down-regulating VEGF and inhibiting VEGF-related pathways might have a synergistic effect with the inhibition of VEGF by anti-VEGF agents[46]. This might partly explain why oral CaD alone has no therapeutic effect on DME, but it can reduce the number of intravitreal injections when combined with anti-VEGF agents within 1-year follow-up period. In addition, this kind of treatment combination was safe proved by the present study. Neither systemic, nor local complication was found during the treatment. The result showed that although CaD inhibited the expression of VEGF by cooperating with anti-VEGF agents, and therefore prolonged the treatment duration of anti-VEGF agents, but it did not increase the risk of treatment secondary to VEGF inhibition. This might explain why the application of CaD alone has no effect in the treatment of DME on the other hand.

## Conclusions

In conclusion, oral CaD combined with intravitreal ranibizumab was demonstrated to have similar effectiveness and safety as anti-VEGF monotherapy for improving visual function and restoring the anatomy of the retina in macular with fewer injections in DME patients. Adding oral CaD might be a feasible way to reduce injection number and decrease the economic burden of treatment in DME patients who received anti-VEGF therapy.

## Abbreviations

BCVA: best corrected visual acuity; BRB: blood retinal barrier; CaD: Calcium dobesilate; CMT: central macular thickness; DM: diabetes mellitus; DME: diabetic macular edema; DR: diabetic retinopathy; FGF: fibroblast growth factor; ICAM-1: intercellular adhesion molecule-1; IL-6: interleukin-6; IVR: intravitreal ranibizumab; MCP-1: monocyte chemotactic protein-1; NO: nitric oxide; OCT: optical coherence tomography; PRN: pro re nata; ROS: reactive oxygen species; VEGF: vascular endothelial growth factor.

## Declarations

### Authors' contributions

Conceptualization: SW. Data Curation: DW HW SW XY JX. Formal analysis: SW DW XY JX. Investigation: SW DW HW. Methodology: SW DW HW. Project administration: SW DW HW XY. Software: SW JX. Supervision: SW DW HW XY JX. Validation: DW HW. Visualization: SW DW HW XY. Writing-original draft: DW HW. Writing-review & editing: SW DW HW. All author(s) had read and approved the final manuscript.

D.W. and H.W. wrote the main manuscript text, S.W. conceived this study, D.W. H.W. X.Y. and J.X. collected the data for this study, and S.W. D.W. X.Y. and J.X. made the formal analysis for this study. All authors reviewed the manuscript.

### Ethics approval and consent to participate

This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Changyi People's Hospital. Informed consent was obtained from all of the patients or their guardians before initiation of intravitreal pharmacotherapy. The medical records were retrospectively reviewed after approval was received from the Institutional Review Board, Changyi People's Hospital.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Availability of data and materials

All data generated or analysed during this study are included in this published article.

## References

1. Holekamp NM: **Overview of diabetic macular edema**. *Am J Manag Care* 2016, **22**(10 Suppl):s284-s291.
2. Tan GS, Cheung N, Simo R, Cheung GC, Wong TY: **Diabetic macular oedema**. *Lancet Diabetes Endocrinol* 2017, **5**(2):143-155.
3. Daruich A, Matet A, Moulin A, Kowalczyk L, Nicolas M, Sellam A, Rothschild PR, Omri S, Gelize E, Jonet L *et al*: **Mechanisms of macular edema: Beyond the surface**. *Prog Retin Eye Res* 2018, **63**:20-68.
4. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M *et al*: **Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study**. *Diabetes Care* 2010, **33**(11):2399-2405.
5. Akkaya S, Acikalin B, Dogan YE, Coban F: **Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity**. *Int J Ophthalmol* 2020, **13**(10):1606-1611.
6. Rosenblatt A, Udaondo P, Cunha-Vaz J, Sivaprasad S, Bandello F, Lanzetta P, Kodjikian L, Goldstein M, Habot-Wilner Z, Loewenstein A *et al*: **A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study**. *Ophthalmology* 2020, **127**(3):377-393.
7. Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM *et al*: **Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema**. *N Engl J Med* 2015, **372**(13):1193-1203.

8. Hodgson N, Wu F, Zhu J, Wang W, Ferreyra H, Zhang K, Wang J: **Economic and Quality of Life Benefits of Anti-VEGF Therapy.** *Mol Pharm* 2016, **13**(9):2877-2880.
9. Riazi-Esfahani M, Riazi-Esfahani H, Ahmadraji A, Karkhaneh R, Mahmoudi A, Roohipoor R, Ghasemi F, Yaseri M: **Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.** *Int Ophthalmol* 2018, **38**(2):585-598.
10. Ahmadi H, Nourinia R, Hafezi-Moghadam A, Sabbaghi H, Nakao S, Zandi S, Yaseri M, Tofghi Z, Akbarian S: **Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.** *Br J Ophthalmol* 2019, **103**(7):922-927.
11. Fazel F, Oliya B, Mirmohammadkhani M, Fazel M, Yadegarfar G, Pourazizi M: **Intravitreal Injections of Bevacizumab Plus Methotrexate versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema: A Randomized, Sham-Controlled Trial.** *J Curr Ophthalmol* 2020, **32**(2):164-169.
12. Altinel MG, Acikalin B, Alis MG, Demir G, Mutibayraktaroglu KM, Totuk OMG, Ardagil A: **Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema.** *Lasers Med Sci* 2021.
13. Kanar HS, Arsan A, Altun A, Aki SF, Hacisalihoglu A: **Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.** *Indian J Ophthalmol* 2020, **68**(1):145-151.
14. Solaiman KA, Diab MM, Abo-Elenin M: **Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.** *Retina* 2010, **30**(10):1638-1645.
15. Eris E, Perente I, Vural E, Vural A, Seymen Z, Celebi ARC, Erdogan G, Ozkaya A, Artunay O: **Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.** *Int Ophthalmol* 2019, **39**(7):1575-1580.
16. Sharma A, Bellala K, Dongre P, Reddy P: **Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.** *Int Ophthalmol* 2020, **40**(1):67-72.
17. Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsua C, Hernandez-Bel L, Montero-Hernandez J: **Intravitreal dexamethasone implant Ozurdex(R) in naive and refractory patients with different subtypes of diabetic macular edema.** *BMC Ophthalmol* 2019, **19**(1):15.
18. Mello Filho P, Andrade G, Maia A, Maia M, Bicas Neto L, Muralha Neto A, Moura Brasil O, Minelli E, Dalloul C, Iglicki M: **Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience.** *Ophthalmologica* 2019, **241**(1):9-16.



19. Allain H, Ramelet AA, Polard E, Bentue-Ferrer D: **Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.** *Drug Saf* 2004, **27**(9):649-660.
20. Berthet P, Farine JC, Barras JP: **Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy.** *Int J Clin Pract* 1999, **53**(8):631-636.
21. Liu J, Li S, Sun D: **Calcium Dobesilate and Micro-vascular diseases.** *Life Sci* 2019, **221**:348-353.
22. Bogdanov P, Sola-Adell C, Hernandez C, Garcia-Ramirez M, Sampedro J, Simo-Servat O, Valeri M, Pasquali C, Simo R: **Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice.** *J Diabetes Complications* 2017, **31**(10):1481-1490.
23. Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG, Group DX-RS: **Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study.** *Graefes Arch Clin Exp Ophthalmol* 2006, **244**(12):1591-1600.
24. Akbulut B: **Calcium dobesilate and oxerutin: effectiveness of combination therapy.** *Phlebology* 2010, **25**(2):66-71.
25. **Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.** *Arch Ophthalmol* 1985, **103**(12):1796-1806.
26. James DGP, Mitkute D, Porter G, Vayalambrone D: **Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.** *Asia Pac J Ophthalmol (Phila)* 2019, **8**(3):200-205.
27. Haritoglou C, Gerstl J, Sauerland C, Kampik A, Ulbig MW, group Cs: **Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial.** *Lancet* 2009, **373**(9672):1364-1371.
28. Zhang X, Liu W, Wu S, Jin J, Li W, Wang N: **Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis.** *Sci China Life Sci* 2015, **58**(1):101-107.
29. Graber R, Farine JC, Losa GA: **Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis.** *Apoptosis* 1998, **3**(1):41-49.
30. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP: **Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina.** *Eur J Pharmacol* 2001, **428**(2):277-286.
31. Rabe E, Jaeger KA, Bulitta M, Pannier F: **Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial.** *Phlebology* 2011, **26**(4):162-168.

32. Hall JF: **Modern management of hemorrhoidal disease.** *Gastroenterol Clin North Am* 2013, **42**(4):759-772.
33. Michal M, Gotti C: **Effect of calcium dobesilate on platelet function.** *Thromb Res* 1988, **51**(6):593-605.
34. Brunet J, Farine JC, Garay RP, Hannaert P: **Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat.** *Eur J Pharmacol* 1998, **358**(3):213-220.
35. Rota R, Chiavaroli C, Garay RP, Hannaert P: **Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.** *Eur J Pharmacol* 2004, **495**(2-3):217-224.
36. Zhou Y, Yuan J, Qi C, Shao X, Mou S, Ni Z: **Calcium dobesilate may alleviate diabetesinduced endothelial dysfunction and inflammation.** *Mol Med Rep* 2017, **16**(6):8635-8642.
37. Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z: **Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function.** *Cell Physiol Biochem* 2018, **51**(3):1119-1133.
38. Zhou Y, Qi C, Li S, Shao X, Ni Z: **Investigation of the Mechanism Underlying Calcium Dobesilate-Mediated Improvement of Endothelial Dysfunction and Inflammation Caused by High Glucose.** *Mediators Inflamm* 2019, **2019**:9893682.
39. Angulo J, Peiro C, Romacho T, Fernandez A, Cuevas B, Gonzalez-Corrochano R, Gimenez-Gallego G, de Tejada IS, Sanchez-Ferrer CF, Cuevas P: **Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.** *Eur J Pharmacol* 2011, **667**(1-3):153-159.
40. Wang Y, Lu YH, Tang C, Xue M, Li XY, Chang YP, Cheng Y, Li T, Yu XC, Sun B *et al*: **Calcium Dobesilate Restores Autophagy by Inhibiting the VEGF/PI3K/AKT/mTOR Signaling Pathway.** *Front Pharmacol* 2019, **10**:886.
41. Fegghi M, Farrahi F, Abbaspour M, Takhtaeian A: **Effect of adding oral calcium dobesilate to laser photocoagulation on the macular thickness in patients with diabetic macular edema: a randomized clinical trial.** *Adv Pharm Bull* 2014, **4**(4):375-378.
42. Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY: **Treatment of Diabetic Macular Edema.** *Curr Diab Rep* 2019, **19**(9):68.
43. Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, Augustin A, de Smet MD, Chhablani J, Tufail A *et al*: **First-line treatment algorithm and guidelines in center-involving diabetic macular edema.** *Eur J Ophthalmol* 2019, **29**(6):573-584.
44. Garcia Layana A, Adan A, Ascaso FJ, Cabrera F, Donate J, Escobar Barranco JJ, Peralta G, Reyes Garcia R, Rodriguez Maqueda M, Ruiz-Moreno JM *et al*: **Use of intravitreal dexamethasone implants in the**

**treatment of diabetic macular edema: Expert recommendations using a Delphi approach.** *Eur J Ophthalmol* 2020, **30**(5):1042-1052.

45. Mahapatra SK, Kumari S: **Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema.** *Indian J Ophthalmol* 2020, **68**(3):490-493.

46. Njau F, Shushakova N, Schenk H, Wulfmeyer VC, Bollin R, Menne J, Haller H: **Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice.** *PLoS One* 2020, **15**(1):e0218494.

## Tables

Table 1: Baseline characteristics of total study population


	IVR (n=48)	IVR+CaD (n=54)	p value
gender (male/female)	31/17	32/22	0.05
age (years)	56.91±9.41	58.35±10.26	0.05
smoking (yes/no)	28/20	29/25	0.05
drinking (yes/no)	19/29	25/29	0.05
comorbidity (yes/no)	17/31	18/36	0.05
course (years)	10.51±4.37	11.05±5.14	0.05
HbA1c (%)	7.45±2.03	7.81±1.92	0.05

Table 2 Changes of CMT and BCVA after the treatment

	BCVA (logMAR)			CMT (μm)		
	IVR (n=48)	IVR+CaD (n=54)	p value	IVR (n=48)	IVR+CaD (n=54)	p value
Baseline	0.35±0.12	0.32±0.15	0.05	427±172	412±185	0.05
At 3 month	0.24±0.09*	0.23±0.10*	0.05	286±69*	277±92*	0.05
At 6 month	0.26±0.11*	0.25±0.08*	0.05	275±73*	271±80*	0.05
At 12 month	0.25±0.13*	0.24±0.11*	0.05	269±77*	249±87*	0.05

\* represent p<0.05 when compared with corresponding parameters at baseline.

## Figures



**Figure 1**

The flowchart indicated the protocol how to select the patients in this study.